Antibody Drug Conjugate (ADC) Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2021 to 2027

The Global Antibody Drug Conjugate (ADC) Market size was valued at USD 4.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 23% from 2021 to 2027. 

The antibody-drug conjugates (ADC) market consists of the sales of antibody-drug conjugates (ADCs). Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies directed against tumor-associated antigens to which highly potent cytotoxic agents are attached using chemical linkers.

Market Segments

By Drug Name:

• Adcetris
• Kadcyla
• Besponsa
• Lumoxiti
• Mylotarg
• Others

By Application :

• Blood Cancer
• Breast Cancer
• Urothelial & Bladder Cancer
• Other Types of Cancer

Key Players

Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Immunomedics Inc., and Oxford BioTherapeutics.

Scope of the Report

The research study analyzes the global Antibody Drug Conjugate(ADC) industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Antibody Drug Conjugate(ADC) Market Report

1. What was the Antibody Drug Conjugate(ADC) Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027).

2. What will be the CAGR of the Antibody Drug Conjugate(ADC) Market during the forecast period (2021-2027)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
4. Which manufacturer/vendor/players in the Antibody Drug Conjugate(ADC) Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.